← Back to front page
United States · Platforms & data · Seeking Alpha

Insmed may be worth $170 to $210 a share in takeover, analyst

Published by Seeking Alpha · United States 49 min ago
JHVEPhoto
JHVEPhoto · Seeking Alpha

Detailed summary

RBC analyst rates Insmed Outperform: a Sanofi takeover could value shares at $170-$210, with a 20%-50% premium plausible.

Insmed (INSM) may be worth $170-$210 a share in a takeover after a report that Sanofi (SNY) is weighing a purchase of the drugmaker, according to an RBC analyst.

Opening of the article, excerpted from Seeking Alpha. To read the rest, open the article on the publisher's site.

Read the full article on Seeking Alpha Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (seekingalpha.com)

Also worth reading